Advanced Enzyme Technologies Limited has informed the Exchange about General Updates -  Approved the appointment of Mr. Shiv Hari Jalan, Proprietor of M/s. Shiv Hari Jalan & Co., Company Secretaries in Practice (C.P. No. 4226) as the Secretarial Auditors of the Company for a period of five consecutive years commencing from the conclusion of the ensuing AGM till the conclusion of 41st AGM subject to the approval of shareholders at the ensuing Annual general Meeting.
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors, at its meeting on May 13, 2025, approved the audited financial results for the quarter and year ended March 31, 2025. On a consolidated basis, total income rose to Rs. 6,699.51 million (vs Rs. 6,605.32 million in FY24), while net profit dipped slightly to Rs. 1,339.74 million (vs Rs. 1,369.51 million). EPS stood at Rs. 11.72 (basic). The Board declared an interim dividend of Rs. 4 per share (200%) for FY26 with a record date of May 17, 2025, and recommended a final dividend of Rs. 1.20 per share (60%) for FY25, subject to shareholder approval at the 36th AGM on July 30, 2025. Additionally, the Board approved the incorporation of a new wholly-owned subsidiary in India and appointed Mr. Shiv Hari Jalan (M/s. Shiv Hari Jalan & Co.) as Secretarial Auditor for five years. Statutory auditor MSKA & Associates issued an unmodified opinion on the financial statements.
Stable operating performance with consolidated revenue growth, though a marginal dip in net profit. Total dividend of Rs. 5.20 per share (interim + final) reflects consistent shareholder returns. Unmodified audit opinion and routine secretarial auditor appointment signal continued governance stability. The new wholly-owned subsidiary suggests planned expansion, which could support future growth.